PPARα agonists such as fibrates have long been clinically used to treat hypertriglyceridemia, whereas PPARγ agonists, such as thiazolidinediones, are approved for type-2 diabetes (T2D) [25,26,27]. Here, PPARG is linked to type 2 diabetes mellitus.